BLA 125526 · Glaxosmithkline LLC
Nucala
Mepolizumab · Subcutaneous Lyophilized Power · Interleukin-5 Antagonist
NovelOrphanLast checked: Nov 20, 2026Latest source record: May 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Nov 4, 2015
Approved uses
6
Original approval plus efficacy supplements
Registered trials
87
34 Phase 3, 15 recruiting
FAERS reports
50,431
31,676 serious, 4,180 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 6, 2025.
NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) 1.1 Maintenance Treatment of Severe Asthma NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations ( 8.4 ), Clinical Studies ( 14.1 )] . Limitations of Use NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . 1.2 Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients aged 18 years and older with inadequate response to nasal corticosteroids. 1.3 Maintenance Treatment of Chronic Obstructive Pulmonary Disease NUCALA is indicated for the add-on maintenance treatment of adult patients with...
Mechanism: Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Mepolizumab binds to IL-5 with a dissociation constant of 100 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface. Inflammation is an important component in the pathogenesis of asthma, CRSwNP, COPD, EGPA, and HES. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators...
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 22, 2025 Supplement 7 · Efficacy OrphanLetterLabel
- Jul 29, 2021 Supplement 18 · Efficacy LetterLabel
- Sep 25, 2020 Supplement 17 · Efficacy · priority review OrphanLabelLetter
- Sep 12, 2019 Supplement 12 · Efficacy LetterLabelPediatric Other
- Dec 12, 2017 Supplement 4 · Efficacy · priority review OrphanLabelLetter
- Nov 4, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
1 products under this application
- NUCALA · MEPOLIZUMAB 100MG · INJECTABLE, SUBCUTANEOUS LYOPHILIZED POWER · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Mepolizumab" as an intervention, any sponsor and status, largest first.
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04718389 · 1,717 participants · Start Jan 26, 2021 · Primary completion Sep 14, 2025
Drug: GSK3511294 (Depemokimab); Mepolizumab and 3 more · For: Asthma
Sites: Birmingham, Alabama; Scottsboro, Alabama; Litchfield Park, Arizona · 397 sites in all
University Hospital, LilleAcademic, hospital or other
NCT06501807 · 900 participants (planned) · Start Jul 11, 2024 · Primary completion Sep 2, 2034
Drug: Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval). · For: Rhinosinusitis Chronic; Nasal Polyps
Sites: Lille, France · 2 sites in all
- Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) PatientsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02105948 · 837 participants · Start Apr 15, 2014 · Primary completion Jan 17, 2017
Drug: Mepolizumab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Newport Beach, California; Rochester, Minnesota; Saint Charles, Missouri · 116 sites in all
- Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04133909 · 806 participants · Start Oct 30, 2019 · Primary completion Aug 8, 2024
Drug: Mepolizumab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Dothan, Alabama; Huntsville, Alabama · 339 sites in all
- Cross-sectional Study for Identification and Description of Severe Asthma PatientsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02293265 · 767 participants · Start Dec 2014 · Primary completion May 2015
Drug: Short Acting Beta Agonist (SABA) · For: Asthma
Sites: Little Rock, Arkansas; Fresno, California; Los Angeles, California · 74 sites in all
- Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02105961 · 674 participants · Start Apr 24, 2014 · Primary completion Jan 16, 2017
Drug: Mepolizumab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Mobile, Alabama; Riverside, California · 169 sites in all
- A Study to Determine Long-term Safety of Mepolizumab in Asthmatic SubjectsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01842607 · 651 participants · Start May 27, 2013 · Primary completion Mar 13, 2015
Drug: Mepolizumab · For: Asthma
Sites: Long Beach, California; Newport Beach, California; Riverside, California · 137 sites in all
- Dose Ranging Efficacy And Safety With Mepolizumab in Severe AsthmaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01000506 · 621 participants · Start Nov 1, 2009 · Primary completion Mar 23, 2012
Drug: Mepolizumab 750; Mepolizumab 250 and 2 more · For: Asthma
Sites: Long Beach, California; Los Angeles, California; Riverside, California · 94 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- asthma12,892
- dyspnoea10,717
- wheezing7,204
- product dose omission issue6,869
- cough5,147
- therapeutic product effect incomplete5,092
- drug ineffective4,736
- pneumonia4,726
- loss of personal independence in daily activities4,281
- fatigue3,151
- sleep disorder due to a general medical condition3,148
- off label use3,137
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2012 | 1 |
| 2013 | 5 |
| 2014 | 7 |
| 2015 | 18 |
| 2016 | 579 |
| 2017 | 1,547 |
| 2018 | 3,014 |
| 2019 | 4,612 |
| 2020 | 5,676 |
| 2021 | 6,089 |
| 2022 | 4,725 |
| 2023 | 5,642 |
| 2024 | 7,767 |
| 2025 | 7,636 |
| 2026 | 3,110 |
Recalls
1 FDA enforcement reports for this application.
Sep 6, 2019 · Class II · Terminated
Temperature Abuse; Product stored and shipped outside of labeled storage requirements.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Nucala (Mepolizumab)
2024 spending
$318M
Beneficiaries
9,062
72,258 claims
Per beneficiary
$35,081
$3,679.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $86,623,799 |
| 2021 | $132,108,367 |
| 2022 | $193,350,671 |
| 2023 | $260,986,344 |
| 2024 | $317,907,428 |
Part B: Nucala (Mepolizumab) · HCPCS J2182
2024 spending
$267M
Beneficiaries
8,671
78,535 claims
Per beneficiary
$30,829
2024 ASP limit $30.47 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $189,665,582 |
| 2021 | $210,518,708 |
| 2022 | $232,903,955 |
| 2023 | $255,126,934 |
| 2024 | $267,320,860 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.
Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. · Ann Rheum Dis 2024 · Systematic Review
- Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype.
Sciurba FC, Criner GJ, Christenson SA, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Nair P, Terrier B, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Comparative Study
- Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Pitre T, Lupas D, Mah J, et al. · COPD 2025 · Systematic Review, Network Meta-Analysis
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Akuthota P, Jayne D, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG, Liu MC, Pavord ID, et al. · N Engl J Med 2014 · Clinical Trial, Phase III, Multicenter Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.